CD274 and cancer: Unlike traditional therapies that directly target cancer cells, immunotherapy is designed to inhibit immune checkpoints, specifically by interfering with the interaction between programmed death protein 1 (PD-1) and its ligands such as PD-L1 (or PD-L2) (86).